| 49th week of 2010 patent applcation highlights part 47 |
| Patent application number | Title | Published |
|---|
| 20100311579 | Reversible Thermosensitive Recording Medium And Method For Producing The Same - A reversible thermosensitive recording medium including a reversible thermosensitive recording layer, a first sheet-shaped base provided adjacent to the reversible thermosensitive recording layer, an electronic information recording module containing a module substrate, and a convex-shaped electronic information recording element and an antenna circuit both disposed on the module substrate, and a first resin layer for bonding the first sheet-shaped base and the electronic information recording module, wherein the first sheet-shaped base has a concave portion on a surface opposite to a surface on which the reversible thermosensitive recording layer is formed, and the electronic information recording element is inserted into the concave portion of the first sheet-shaped base. | 2010-12-09 |
| 20100311580 | Active Compound Combinations - The invention relates to active compound combinations, in particular a fungicidal and/or insecticidal composition, comprising Isotianil (3,4-dichloro-N-(2-cyanophenyl)-5-isothiazolecarboxamide, CAS No 224049-04-1) and another insecticide flubendiamide (CasNo 272451-65-7) and optionally one further insecticide of the neonicotinoids. Moreover, the invention relates to a method for curatively or preventively controlling the phytopathogenic fungi and/or microorganisms and/or pests of plants or crops, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed. | 2010-12-09 |
| 20100311581 | Azolylmethyloxiranes, use Thereof and Agents Containing the Same - The present invention relates to triazolylmethyloxiranes of the formula I | 2010-12-09 |
| 20100311582 | CHEMICAL COMPOUNDS - A compound of the formula (I) where, for example, W, X and Y are each CH; R | 2010-12-09 |
| 20100311587 | DEFOLIANT - A mixture, comprising
| 2010-12-09 |
| 20100311588 | SYNERGISTIC HERBICIDAL COMBINATIONS COMPRISING TEMBOTRIONE - A description is given of herbicidal compositions comprising
| 2010-12-09 |
| 20100311591 | HERBICIDAL FORMULATIONS FOR TRIETHANOLAMINE SALTS OF GLYPHOSATE - A high strength herbicidal composition including water; glyphosate, predominantly in the form of a combination of triethanolamine salt and potassium salt in solution in the water in an amount of about 350 grams or greater of acid equivalent per liter of the composition wherein the composition is formulated to include triethanolamine in an amount to form a salt with about 10% or greater, by weight, of total glyphosate and to include potassium in an amount to form a salt with a percentage of total glyphosate so that the combined sum of glyphosate in triethanolamine and potassium salts is more than 50% of total glyphosate; and optionally, one or more surfactants and/or one or more humectants. | 2010-12-09 |
| 20100311592 | USE OF 2-IODO-N 4-METHOXY-6-METHYL-1,3,5-TRIAZINE-2-YL CARBAMOYL BENZENESULFONAMIDE AND/OR SALTS THEREOF FOR COMBATING UNDESIRED PLANT GROWTH IN SELECTED USEFUL PLANT CROPS OR NON-CULTIVATED LAND - The invention relates to the use of 2-iodo-N-[(4-methoxy-6-methyl-1,3,5-triazin-2-yl)carbamoyl]benzenesulfonamide and/or its salts for the selective control of unwanted vegetation (a) by the pre-emergence method (PE) in crop plants such as wheat (durum wheat and common wheat), corn, soybeans, sugar beet, sugar cane, rice, cotton, beans, peas, flax, barley, oats, rye, triticale, potatoes and millet (sorghum) and also (b) by the post-emergence method (PO) in crop plants such as barley, oats, rye, triticale, potatoes, broad beans, flax, pasture land and greens/lawns, where the crops mentioned above in each case include summer and winter varieties and also cultivars modified by genetic engineering or by mutagenesis, and (c) on non-crop land and in plantation crops. | 2010-12-09 |
| 20100311593 | Haloalkylmethyleneoxyphenyl-substituted ketoenols - The invention relates to novel compounds of the formula (I), | 2010-12-09 |
| 20100311594 | 3-HALO-(ARLY)-4-IMINOTETRAHYDROPICOLINATES AND THEIR USE AS HERBICIDES - 3-Halo-6-(aryl)-4-iminotetrahydropicolinic acids having mono-, di- tri- and tetra-substituted aryl substituents in the 6-position, and their acid derivatives, are herbicides demonstrating a broad spectrum of weed control. | 2010-12-09 |
| 20100311595 | LIPOPHILIC DRUG DELIVERY VEHICLE AND METHODS OF USE THEREOF - The invention provides compositions and methods for delivery of a bioactive agent to an individual. Delivery vehicles are provided that include a bioactive agent in disc shaped particles that include one or more lipid binding polypeptides circumscribing the perimeter of a lipid bilayer in which the bioactive agent is localized. Chimeric lipid binding polypeptides are also provided and may be used to add additional functional properties to the delivery particles. | 2010-12-09 |
| 20100311596 | CORE-SATURATED SUPERCONDUCTIVE FAULT CURRENT LIMITER AND CONTROL METHOD OF THE FAULT CURRENT LIMITER - A core-saturated superconductive fault current limiter and a control method of the fault current limiter. The fault current limiter includes a superconductive magnet ( | 2010-12-09 |
| 20100311597 | METHODS FOR SEQUENCE A POLYNUCLEOTIDE TEMPLATE - The invention relates to methods for pairwise sequencing of a polynucleotide template which result in the sequential determination of nucleotide sequence in two distinct and separate regions of the polynucleotide template. | 2010-12-09 |
| 20100311598 | SYSTEM AND METHOD FOR EDITING AND MANIPULATING DNA - A system and method for planning, manipulating, processing and editing DNA molecules utilizing a core operation on a given input DNA molecule to produce a targeted DNA molecule. | 2010-12-09 |
| 20100311601 | INDEX OF GENOMIC EXPRESSION OF ESTROGEN RECEPTOR (ER) AND ER-RELATED GENES - The present invention provides the identification and combination of genes that are expressed in tumors that are responsive to a given therapeutic agent and whose combined expression can be used as an index that correlates with responsiveness to that therapeutic agent. One or more of the genes of the present invention may be used as markers (or surrogate markers) to identify tumors that are likely to be successfully treated by that agent or class of agents such as hormonal or endocrine therapy or chemotherapy. | 2010-12-09 |
| 20100311602 | Sequencing method - The present invention relates, e.g., to a method for isolating a DNA molecule of interest in a form suitable for sequencing at least a portion of the DNA by a high throughput sequencing method, comprising (a) digesting a double-stranded (ds) DNA molecule with two different restriction enzymes, A and B, to generate a ds form of the DNA molecule of interest, which is bounded by the two restriction enzyme cleavage products, and (b) attaching to each end of the DNA molecule of interest an adaptor molecule which comprises at one end a restriction enzyme cleavage site that is compatible with the restriction enzyme A or the restriction enzyme B cleavage product, and which also comprises a sequence and/or element that allows the DNA of interest to be sequenced with a high throughput sequencing apparatus. The method can be adapted for sequencing DNA with a variety of high throughput sequencing apparatuses, including machines manufactured by the 454, Illumina (Solexa Sequencing technology) and ABI (SOLiD™ Sequencing technology) companies. A method is also described for sequencing regulatory elements within a cell, comprising subjecting a collection of ds DNA molecules that are enriched for regulatory elements and that are generated by digestion with two restriction enzymes, A and B, which generate sticky ends, to an isolation method of the invention, and sequencing the collection of ds DNA molecules with a high throughput sequencing apparatus. | 2010-12-09 |
| 20100311605 | SENSING PLATFORM - A sensing platform includes: a plurality of metal nanoparticles; a plurality of aggregate inducers each comprising first and second functional groups different from each other, and the first functional group of the aggregate inducers being in contact with the metal nanoparticles; and a plurality of recognition molecules for binding the metal nanoparticles and for interacting with a target to recognize the target, wherein the second functional group of the aggregate inducers is free from being in contact with the metal nanoparticles, and is used to induce the metal nanoparticles to aggregate after the recognition molecules interact with the target. | 2010-12-09 |
| 20100311606 | PHARMACOGENOMIC CELL LINE PANEL AND USE THEREOF - Materials and methods for evaluating cellular response to therapeutic agents. | 2010-12-09 |
| 20100311607 | METHOD FOR RAPID IDENTIFICATION OF MICROORGANISMS - The present invention relates, in general, to probes, methods, and kits used to determine the presence or absence of a microorganism in a sample. The probes, methods, and kits comprise at least one capture probe and/or at least one detector probe. | 2010-12-09 |
| 20100311608 | METHOD TO PREPARE MAGNETIC BEADS CONJUGATED WITH SMALL COMPOUNDS - It is an object of the present invention to provide a method for stably and efficiently binding a compound to magnetic beads. The present invention relates to a method for producing compound-bound magnetic beads, which comprises: allowing a compound to come into contact with magnetic beads, on the surface of each of which a photoreactive compound has bound; extending the magnetic beads together with the compound on a support; and applying light to the magnetic beads to form a covalent bond between the photoreactive compound and the compound. | 2010-12-09 |
| 20100311611 | SYSTEMS FOR AND METHODS OF CHARACTERIZING REACTIONS - An automated and computerized system for characterizing kinetic activities is disclosed. The system includes an optical unit with a controller chip. The controller chip has multiple reaction cells for simultaneously reacting samples of the catalyst under a range of reaction conditions and for optically monitoring the kinetic activity within each of the reaction cells: The system also preferably includes a temperature controller in thermal contact with the controller chip and an actuation device coupled to the controller chip for injecting and mixing samples of the catalyst with reagents into each of the reaction cells to form a product. | 2010-12-09 |
| 20100311612 | Compositions and Methods for Making Mutations in Cell Lines and Animals - The present invention is directed generally to reduction or inactivation of gene function or gene expression in cells in vitro and in multicellular organisms. The invention encompasses methods for mutating cells using a combination of mutagens, particularly wherein at least one mutagen is an insertional mutagen, to achieve homozygous gene mutation or mutation of multiple genes required cumulatively to achieve a phenotype to create knock-outs, knock-downs, and other modifications in the same cell. The invention is also directed to cells (and libraries thereof) and organisms created by the methods of the invention, including those in which at least one of the genes created by insertional mutagenesis is tagged by means of the insertion sequences thereby allowing identification of the mutated gene(s). The invention is also directed to libraries of mutated cells and their uses. The invention is also directed to methods of identifying mutations with methods of the invention, in cells (and libraries thereof) and organisms, by means of the insertional tag. | 2010-12-09 |
| 20100311617 | GRAFT COPOLYMER AS A GAS HYDRATE INHIBITOR - Graft copolymers based on a polyamide which was reacted with maleic anhydride and which has at least one vinylically unsaturated side chain are proposed, this grafted side chain containing at least one representative selected from a) N-vinylcaprolactam and/or b) N-vinylpyrrolidone. Inter alia, natural but also synthetic polyamides are provided as preferred polyamide components. Such graft copolymers, but also generally polyamide-based graft copolymers composed of at least one side chain containing ethylenically unsaturated compounds, are in general suitable in construction chemistry applications but also in the development, exploitation and completion of underground mineral oil and natural gas deposits and in deep wells and moreover in the extraction and the transport of oil or gas and here in particular as a gas hydrate inhibitor. | 2010-12-09 |
| 20100311618 | Fluid Treatment Systems, Compositions and Methods for Metal Ion Stabilization in Aqueous Solutions and/or Enhanced Fluid Performance - Fluid treatment systems and compositions are provided including (a) at least one material including (1) at least one carboxylic acid functional group and (2) at least one sulfur-containing group selected from the group consisting of sulfonyl functional groups, sulfonate functional groups and mixtures thereof; (b) at least one friction reducing agent selected from the group consisting of guar gums, polyacrylamides, hydratable cellulosic materials, viscoelastic surfactants, and mixtures thereof; and (c) at least one scale control agent. The fluid treatment systems and compositions can be used to treat aqueous systems, for example as fracturing fluids for treating aqueous compositions found in subterranean formations. Methods for inhibiting formation and/or precipitation of metal oxides in an aqueous composition using the fluid treatment systems or compositions also are provided. | 2010-12-09 |
| 20100311625 | BIOLUBRICANT ESTERS FROM THE ALCOHOLS OF UNSATURATED FATTY ACIDS - The present invention is generally directed to triester-based lubricant compositions. The present invention is also directed to methods of making these and other similar lubricant compositions. In some embodiments, the methods for making such triester-based lubricants utilize a biomass precursor comprising mono-unsaturated fatty acids, wherein such mono-unsaturated fatty acids are reduced to mono-unsaturated fatty alcohols en route to the synthesis of triester species for use as/in the triester-based lubricant compositions. Subsequent steps in such synthesis may employ carboxylic acids and/or acyl halides/anhydrides derived from biomass and/or Fischer-Tropsch synthesis. | 2010-12-09 |
| 20100311626 | CONTACT LENS CLEANER - The invention relates to a contact lens cleaning agent which contains 0.001 to 5% w/w of an organic peroxy acid as well as to the use of organic peroxy acids for contact lens cleaning purposes. | 2010-12-09 |
| 20100311629 | METHOD FOR REMOVING WATER-INSOLUBLE SUBSTANCES FROM SUBSTRATE SURFACES - The invention relates to a method for removing water-insoluble substances from substrate surfaces by means of a solid dry carrier comprising hydrophobin. | 2010-12-09 |
| 20100311630 | SURFACE TREATMENT COMPOSITION, SURFACE TREATMENT METHOD, AND METHOD FOR MANUFACTURING SEMICONDUCTOR DEVICE - A surface treatment composition of this invention is a composition for treating a metal wiring-including surface of a semiconductor substrate, which includes a compound (A) represented by a specific structural formula and a solvent (B) having a boiling point at one atmospheric pressure of 50 to 300° C., and has a pH of 4 to 11. | 2010-12-09 |
| 20100311631 | LOW VOLATILE ORGANIC COMPOUNDS CLEANER COMPOSITION - Disclosed herein are low volatile organic compound cleaner compositions which include a diethylene glycol monoalkyl ether, benzyl alcohol, and a fluorosurfactant. Also disclosed are low volatile organic compound cleaner compositions which include a diethylene glycol monoalkyl ether, benzyl alcohol, and an ethanolamine. Methods of using the compositions are also provided. | 2010-12-09 |
| 20100311632 | Controlled release materials - The invention relates to polymers whose water solubility may be triggered by changes in pH, salt concentration, concentration of surfactant or a combination of both. The polymer is a copolymer or terpolymer containing from 2 to 60 mole percent of an amine functionality that has been neutralized with a fixed acid. Specifically films formed from these polymers will be insoluble at a higher pH, but will become soluble at a lower pH. The polymers are also insoluble at a higher salt concentration, but become soluble at a lower salt concentration. The polymers can be used to coat or encapsulate active ingredients, that are released based on changes in the environment, such as in the rinse cycle of a dishwasher or laundry washing machine. | 2010-12-09 |
| 20100311635 | Subtilases - The present invention relates to novel JP170 like subtilases from wild-type bacteria, hybrids thereof and to methods of construction and production of these proteases. Further, the present invention relates to use of the claimed subtilases in detergents, such as a laundry or an automatic dishwashing detergent. | 2010-12-09 |
| 20100311636 | DETERGENT COMPOSITIONS AND THE USE OF ENZYME COMBINATIONS THEREIN - New detergent compositions and the use of enzyme combinations therein are disclosed. The compositions have enhanced stability of non protease enzymes present in the compositions. | 2010-12-09 |
| 20100311639 | INHIBITORS OF NCCA-ATP CHANNELS FOR THERAPY - Methods and compositions are provided that are utilized for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury. In particular, the methods and compositions are inhibitors of a particular NCca-ATP channel and include, for example, inhibitors of SUR1 and/or inhibitors of TRPM4. Kits for treatment and/or prevention of intraventricular hemorrhage or progressive hemorrhagic necrosis (PHN), particularly following spinal cord injury, are also provided. The present invention also concerns treatment and/or prevention of intraventricular hemorrhage in infants, including premature infants utilizing one or more inhibitors of the channel is provided to the infant, for example to brain cells of the infant. | 2010-12-09 |
| 20100311640 | SELF-ASSEMBLING PEPTIDE INCORPORATING MODIFICATIONS AND METHODS OF USE THEREOF - The invention provides a self-assembling peptide comprising (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain that does not self-assemble in isolated form. In certain embodiments of the invention the second amino acid domain comprises a biologically active peptide motif, e.g., a peptide motif found in a naturally occurring protein, or a target site for an interaction with a biomolecule. In certain embodiments of the invention the naturally occurring protein is a component of the extracellular matrix, e.g., a component of the basement membrane. The invention further provides scaffolds comprising the self-assembling peptides and methods of using the scaffolds including for cell culture, tissue engineering, and tissue repair. | 2010-12-09 |
| 20100311643 | USE OF GLP-1 AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent. | 2010-12-09 |
| 20100311644 | ISOZYME-SPECIFIC ANTAGONISTS OF PROTEIN KINASE C - A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of εPKC are also disclosed. | 2010-12-09 |
| 20100311645 | PROTEINS FROM THE WEBS OF NEPHILENGYS CRUENTATA, AVICULARIA JURUENSIS AND PARAWIXIA BISTRIATA SPIDERS ISOLATED FROM BRAZILIAN BIODIVERSITY - The Present invention relates to molecules isolated from the nucleic acid that encodes spider web proteins or fragments of these or other derivatives of these. The invention also refers to a chimerical gene and an expression vector containing molecules isolated from the nucleic acid that codes for proteins related to the webs of | 2010-12-09 |
| 20100311646 | METHOD OF INHIBITING CLOSTRIDIUM DIFFICILE BY ADMINISTRATION OF ORITAVANCIN - Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of | 2010-12-09 |
| 20100311647 | USE OF MELANOCORTINS TO TREAT INSULIN SENSITIVITY - The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance. | 2010-12-09 |
| 20100311648 | MELANOCORTIN RECEPTOR-SPECIFIC PEPTIDES - The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) | 2010-12-09 |
| 20100311657 | HEMOGLOBIN COMPOSITIONS - The invention provides compositions containing hemoglobin, particularly PEGylated hemoglobin. The PEGylated hemoglobin molecule is capable of transferring oxygen or carbon monoxide bound thereto to a tissue with which it is in proximity. Exemplary PEGylated hemoglobin formulations of the invention are virally inactivated. Various compositions of the invention include deoxygenated hemoglobin, which may be conjugated with one or more water-soluble polymer. PEGylated hemoglobin includes those species in which the iron atom of the hemoglobin molecule is not bound to oxygen or any other species, and hemoglobin molecules in which a species other than oxygen, e.g., carbon monoxide, is bound to the iron atom. The compositions of the invention are formulated as hypo-, iso- or hypertonic solutions of the PEGylated hemoglobin. The compositions are of use to treat and/or ameliorate disease, injury and insult by providing for the oxygenation of tissues and/organs. | 2010-12-09 |
| 20100311658 | MODIFIED VITAMIN K-DEPENDENT POLYPEPTIDES - The invention provides vitamin K-dependent polypeptides with enhanced membrane binding affinity. These polypeptides can be used to modulate clot formation in mammals. Methods of modulating clot formation in mammals are also described. | 2010-12-09 |
| 20100311665 | Method and Composition for Potentiating an Opiate Analgesic - Composition and methods of treating pain and reducing or reversing tolerance to opiate analgesics are disclosed. The composition and method utilize an opiate analgesic and an endothelin antagonist as active agents to treat pain in mammals, including humans. | 2010-12-09 |
| 20100311666 | COSMETIC USE OF A PROTEIN BELONGING TO THE RIBONUCLEASE FAMILY - The present invention relates to the use, in cosmetics and in therapeutics, of at least one antimicrobial protein belonging to the ribonuclease family, ribonuclease 7, or of polypeptides derived from said protein, notably as a marker for evaluating the condition of the epidermis. It further relates to the use of at least one polypeptide according to the invention, of at least one nucleic acid sequence coding for a polypeptide according to the invention, or of at least one agent that modulates the expression or the activity, notably biological, of said polypeptide or of its interaction with an element of the extracellular matrix, for the preparation of compositions intended for the prevention and/or treatment of skin disorders. | 2010-12-09 |
| 20100311667 | NOVEL COMPOUNDS, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME - A compound of the formula I: R-A-Gly-His-B (I) wherein: A and B are independently of each other a L-lysine residue, a D-lysine residue, or a L- or D-lysine residue in which the NH | 2010-12-09 |
| 20100311668 | PERSONAL CARE AND COSMETIC COMPOSITION CONTAINING TETRAPEPTIDES WITH THE MOTIFS GX1X2G, PX1X2P, OR PX1X2K - The present invention relates to topical personal care and skin care compositions comprising: a) a safe and effective amount of a tetrapeptide selected from the group of tetrapeptides with the motif GX | 2010-12-09 |
| 20100311669 | COMPOUNDS THAT BIND TO P185 AND METHODS OF USING THE SAME - Novel peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed. | 2010-12-09 |
| 20100311670 | Conjugates of hydroxyalkyl starch and a protein, prepared by native chemical ligation - Conjugates of an active substance and hydroxyalkyl starch (HAS) are provided herein. The active substance and the HAS are linked by a chemical moiety having a structure according to formula (I) wherein Y is O or S, and X is SH or (F). The conjugate has a structure according to formula (IV) wherein HAS′ is a residue of HAS or a derivative thereof linked to the thioester group, and AS′ is a residue of the active substance or derivative thereof linked to the alpha-X beta-amino group; or a structure according to formula (V) wherein HAS′ is a residue of HAS or derivative thereof linked to the alpha-X beta-amino group, and AS′ is a residue of the active substance or derivative thereof linked to the thioester group, and wherein the group —(C═Y) is derived from the thioester group —(C═Y)—S—R′ and the group HN—CH—CH | 2010-12-09 |
| 20100311671 | TRANSDERMAL DELIVERY OF PKC MODULATORY PEPTIDES THROUGH MICROPORATED SKIN - Disclosed herein are methods for transdermal delivery of PKC modulatory peptides. Generally, methods comprise the delivery of an isozyme specific PKC peptide modulator through skin that has been microporated, e.g., with an array of microneedles. Such methods may be used to administer therapeutically effective amounts of an isozyme selective PKC peptide inhibitor or activator. | 2010-12-09 |
| 20100311672 | VESICULINS - The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and antibodies, and methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of a composition of the invention, including but not limited to glucose metabolism diseases. | 2010-12-09 |
| 20100311675 | NOVEL METHOD FOR PREPARING PURIFIED EXTRACTS OF HARPAGOPHYTUM PROCUMBENS - The present invention relates to a method for preparing a concentrated extract of | 2010-12-09 |
| 20100311676 | COMPOSITIONS CONTAINING SESAMIN-CLASS COMPOUND(S) AND QUERCETIN GLYCOSIDE(S) - The purpose of the present invention is to provide a means of enhancing the bodily absorption of sesamin-class compounds. By using sesamin-class compounds and quercetin glycosides in combination, the bodily absorption of the sesamin-class compounds can be enhanced. | 2010-12-09 |
| 20100311681 | STABLE 6-METHOXY-2',3'-DIDEOXYGUANOSINE, METHOD FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME - A stable 6-methoxy-2′,3′-dideoxyguanosine comprises 6-30% water content. It is prepared by absorbing water in 6-methoxy-2′,3′-dideoxyguanosine with less than 6% water content at low temperature and certain humidity, or drying 6-methoxy-2′,3′-dideoxyguanosine with more than 30% water content. The stable 6-methoxy-2′,3′-dideoxyguanosine can be used to prepare medicament composition, and be used to manufacture pharmaceutical for fighting hepatitis B virus or HIV. | 2010-12-09 |
| 20100311682 | ANTIMELANCHOLIC MEDICINE PREPARED WITH JUJUBE CAMP MATERIALS - The antimelancholic medicine or health products prepared with jujuba cAMP materials and the preparative method are provided in the present invention. | 2010-12-09 |
| 20100311683 | CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES - The present invention provides methods of treating a patient having a higher risk myelodysplastic syndrome, which comprises administering to a patient having a higher risk myelodysplastic syndrome a therapeutically effective amount of a cytidine analog. The cytidine analog includes 5-aza-2′-deoxy cytidine, 5-azacytidine, 5-aza-2′-deoxy- 2′,2′-difluorocytidine, 5-aza-2-40 -deoxy-2′-fluorocytidine, 2′-deoxy-2′,2′-difluorocytidine, cytosine 1-β-D-arabinofuranoside, 2(1H) pyrimidine riboside, 2′-cyclocytidine, arabinofuanosyl-5-azacytidine, dihydro-5-azacytidine, N | 2010-12-09 |
| 20100311684 | NOVEL TRICYCLIC NUCLEOSIDES OR NUCLEOTIDES AS THERAPEUTIC AGENTS - Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively. | 2010-12-09 |
| 20100311687 | POLYSACCHARIDES DERIVATISED WITH CITRIC ACID - Non-crosslinked derivatives of oligo/polysaccharides of formula I, wherein: X is OH, OM, NH—R | 2010-12-09 |
| 20100311688 | OPHTHALMIC FORMULATIONS, METHODS OF MANUFACTURE, AND METHODS OF USING SAME - The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye. Methods of manufacture are also provided. | 2010-12-09 |
| 20100311691 | COMPOSITIONS OF S-ALKYLISOTHIOURONIUM DERIVATIVES FOR TREATING UPPER RESPIRATORY CONGESTION - The present invention provides intranasal pharmaceutical compositions comprising an S-alkylisothiouronium derivative and methods of treating or alleviating upper respiratory and oral-pharyngeal congestions by pharmaceutical compositions comprising the S-alkylisothiouronium derivative. | 2010-12-09 |
| 20100311692 | Pharmaceutical Formulation Containing Choline Alfoscerate - The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments. | 2010-12-09 |
| 20100311695 | HYDROXY-BISPHOSPHONIC ACID DERIVATIVES AS VECTOR TARGETING BONE TISSUE - The present invention relates to hydroxy-bisphosphonic acid derivatives corresponding to general formula (I): in which: -n and m denote, independently of one another, an integer ranging from 1 to 4, —X denotes an oxygen atom or an N—R3 group, —R1 and R3 denote, independently of one another, a linear or branched C | 2010-12-09 |
| 20100311696 | TOPICAL SKIN TREATMENT COMPOSITION - The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin. The present invention further relates to the topical application to the skin of such compositions, and/or preparations containing them, for the prevention and/or treatment of damage to skin. | 2010-12-09 |
| 20100311699 | NOVEL CARBOXYLIC ACID 4-PHENYLAZO-PHENYL ESTER DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS - This invention relates to novel carboxylic acid 4-phenylazo-phenyl ester derivatives useful as monoamine neurotransmitter re-uptake inhibitors. | 2010-12-09 |
| 20100311700 | Transdermal preparation for external use containing nonsterioidal antiinflammatory/analgesic agent - A transdermal preparation for external use which contains a photosensitive NSAID and a UV blocker having a high ability to migrate into the skin. Thus, it becomes possible to ensure, in a transdermal preparation for external use containing a NSAID, the inhibition of the onset of light-induced non-immunological or immunological skin symptoms by the above-described component. | 2010-12-09 |
| 20100311703 | NEW COMPOUNDS AS ADENOSINE A1 RECEPTOR ANTAGONISTS - This compounds correspond to the formula (I), where: R | 2010-12-09 |
| 20100311704 | PHARMACEUTICAL DELIVERY SYSTEMS FOR TREATMENT OF SUBSTANCE ABUSE AND OTHER ADDICTIONS - Disclosed are injectable pharmaceutical compositions that contain a therapeutically effective amount of an anti-addictive agent, an anti-inflammatory agent, and a pharmaceutically acceptable liquid carrier, methods of making the compositions, and uses thereof for treating addictions including substance abuse (or addiction to an abused substance) and addictive or compulsive behavior, by administering the composition to a subject in need thereof. | 2010-12-09 |
| 20100311707 | CONTROLLED RELEASE DELIVERY SYSTEM FOR NASAL APPLICATIONS AND METHODS OF TREATMENT - This invention relates to a gel formulation for nasal administration of a controlled release formulation of hormones to the systemic circulation and/or to the brain. The special lipophilic or partly lipophilic system of the invention leads to higher bioavailability of the active ingredient caused by sustained serum levels in plasma but also leads to a more favorable serum level profile. The special lipophilic or partly lipophilic system also allows for the modulation of brain functioning. The invention also relates to the nasal administration of steroid hormones for treatment of female sexual dysfunction (FSD) or female arousal disorder. | 2010-12-09 |
| 20100311708 | USE OF NOR-BILE ACIDS IN THE TREATMENT OF ARTERIOSCLEROSIS - The present invention relates to the use of nor-bile acids and their pharmaceutically acceptable salts, esters and/or derivatives in the treatment arteriosclerosis. | 2010-12-09 |
| 20100311713 | Novel Azetidine Compounds Useful in the Treatment of Functional Gastrointestinal Disorders, Ibs and Functional Dyspepsia - The present invention relates to new azetidine compounds, to pharmaceutical compositions containing them and the use of said compounds in the treatment of functional gastrointestinal disorders, IBS and functional dyspepsia. The compounds are neurokinin (NK) antagonists. The present invention further relates to processes for the preparation of the compounds. | 2010-12-09 |
| 20100311714 | 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS - The invention relates to the use of 1H-imidazo[4,5-c]quinolinone compounds and salts thereof in the treatment of protein and/or lipid kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases; 1H-imidazo[4,5-c]quinolinone compounds for use in the treatment of protein and/or lipid kinase dependent diseases; a method of treatment against said diseases, comprising administering the 1H-imidazo[4,5-c]quinolinone compounds to a warm-blooded animal, especially a human; pharmaceutical preparations comprising an 1H-imidazo[4,5-c]quinolinone compounds, especially for the treatment of a protein and/or lipid kinase dependent disease; novel 1H-imidazo[4,5-c]quinolinone compounds; and a process for the preparation of the novel 1H-imidazo[4,5-c]quinolinone compounds. | 2010-12-09 |
| 20100311715 | ALPHA CARBOLINES AND USES THEREOF - This invention provides alpha-carboline compounds of formula I: | 2010-12-09 |
| 20100311716 | USE OF INHIBITORS OF JUN N-TERMINAL KINASES TO TREAT GLAUCOMA - Compositions and methods for lowering IOP and/or providing neuroprotection are disclosed. The compositions and methods are particularly directed to the use inhibitors of Jun N-terminal kinases (JNK) to lower IOP and/or provide neuroprotection. | 2010-12-09 |
| 20100311719 | Prevention of Obesity in Antipsychotic, Antidepressant and Antiepileptic Medication - O-(3-piperidino-2-hydroxypropyl)-nicotinic amidoxime or a pharmaceutically suitable acid addition salt thereof (BGP-15) can be used for the prevention or reduction of weight gain or obesity in a patient treated with an antipsychotic drug or an antidepressant drug or an antiepileptic drug. | 2010-12-09 |
| 20100311720 | Spiroindoline Modulators of Muscarinic Receptors - The present invention relates to spiroindoline modulators of muscarinic receptors. The present invention also provides compositions comprising such spiroindoline modulators, and methods therewith for treating muscarinic receptor mediated diseases. | 2010-12-09 |
| 20100311721 | COMPOUNDS - The present invention encompasses compounds of general formula (1) | 2010-12-09 |
| 20100311722 | NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION - The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated with withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone. | 2010-12-09 |
| 20100311725 | NORIBOGAINE IN THE TREATMENT OF PAIN AND DRUG ADDICTION - The present invention is directed to methods of treating patients for pain by administering noribogaine. Noribogaine may also be used to treat patients for the symptoms associated withdrawal from drug dependency. In the latter case, the noribogaine treatment should be supplemented with the administration of an opioid antagonist such as naloxone. | 2010-12-09 |
| 20100311726 | REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR - The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted Aβ. The metabolic processing of other γ-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing Aβ production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing Aβ production. | 2010-12-09 |
| 20100311731 | Fluoroquinolone Carboxylic Acid Molecular Crystals - A molecular crystal form of (R)-(+)-7-(3-amino-2,3,4,5,6,7-hexahydro-1H-azepin-1-yl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid is characterized by at least one of: (a) an X-ray powder diffraction (“XRPD”) spectrum that comprises peaks at 2θ angles of 10.6, 15, 19.7, 21.1, and 22°±0.2°; (b) a DSC melting peak at 288° C.; (c) a | 2010-12-09 |
| 20100311732 | NOVEL HETEROCYCLIC COMPOUNDS - The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV). | 2010-12-09 |
| 20100311733 | THIADIAZINONE DERIVATIVES - Compounds of the formula (I), in which R | 2010-12-09 |
| 20100311734 | Spiro Compounds Useful as Antagonists of the H1 Receptor - The invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders. | 2010-12-09 |
| 20100311737 | PYRIMIDO [4,5-B] -OXAZINES FOR USE AS DGAT INHIBITORS - Compounds of formula (I) or salts thereof, wherein A, and R | 2010-12-09 |
| 20100311738 | Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor Antagonists - The present invention relates to a pharmaceutical composition in the form of a storage-stable solution for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonists, comprising a) an ultrashort-effective β-adrenoreceptor antagonist and/or a pharmaceutically acceptable salt thereof, b) water, and c) a cyclodextrin and/or a functional cyclodextrin derivative. The composition according to the invention has high stability, even without the presence of additional adjuvants. | 2010-12-09 |
| 20100311739 | Naphthalene Diimide Compounds - The invention relates to novel compounds which are naphthalene diimides of general formula (I). The compounds are used in therapy, particularly in cancer treatment. | 2010-12-09 |
| 20100311740 | IMIDAZOPYRIDINE DERIVATIVES AS ACID PUMP ANTAGONISTS - This invention relates to newly identified imidazopyridine compounds of formula (I), to the use of such compounds in treating GERD and the like. | 2010-12-09 |
| 20100311751 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT - A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 2010-12-09 |
| 20100311752 | Substituted pyridazine derivatives - The present invention is directed to compounds having histamine H | 2010-12-09 |
| 20100311753 | C5aR ANTAGONISTS - Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors. | 2010-12-09 |
| 20100311754 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase - Naphthalene-based compounds having linked heterocyclic and aromatic rings capable of inhibiting P38, methods for inhibiting P38 in vivo or in vitro, diagnostics for determining activity in the treatment of P38 and/or cytokine-associated conditions and methods for treating conditions associated with P38 activity or cytokine activity; more particularly naphthalene-based compounds of Formula (I) having a morpholine heterocyclic ring, and methods of use thereof. | 2010-12-09 |
| 20100311755 | 1,2,4,-TRIAZIN-3,5-DIONE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR - The invention relates to compounds of the formula I: | 2010-12-09 |
| 20100311756 | METHODS FOR DELAYING THE PROGRESSION OF AT LEAST ONE OF CARDIAC HYPERTROPHY, CARDIAC REMODELING OR LEFT VENTRICULAR FUNCTION OR THE ONSET OF HEART FAILURE IN SUBJECTS IN NEED OF TREATMENT THEREOF - The present invention relates to methods for reducing the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular dysfunction following a cardiac insult in a subject in need of treatment thereof. Moreover, the present invention also relates to methods of delaying the onset of heart failure symptoms or reducing the incidence of cardiovascular events following a cardiac insult in a subject in need of treatment thereof. | 2010-12-09 |
| 20100311759 | ANTIPARASITIC AGENT FOR FISH AND METHOD OF CONTROLLING PROLIFERATION OF FISH PARASITES - An antiparasitic agent for fish containing an inhibitor of folate synthesis and/or an inhibitor of folate activation as the active substance(s). A combination preparation composed of an inhibitor of folate synthesis and an inhibitor of folate activation is preferable, and a sulfonamide is preferable for the inhibitor of folate synthesis. A dihydrofolate reductase inhibitor, a folate antagonist, etc., can be used as the inhibitor of folate activation. | 2010-12-09 |
| 20100311760 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein | 2010-12-09 |
| 20100311767 | Method for the treatment of amyloidoses - The present invention relates to a method for the treatment of an amyloidosis such as Alzheimer's disease in a subject in need thereof, characterized in that it comprises administering an agonist of the P/Q type voltage-gated presynaptic calcium channel to said subject. | 2010-12-09 |
| 20100311768 | USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT - The invention relates to the use of purine derivatives in the manufacture of a medicament for treating pathological conditions in which an imbalance between cell division and apoptosis is involved, and more particularly in which excessive apoptosis is responsible for the pathological condition. According to the invention, a purine derivative of formula I is used. The invention finds use in the pharmaceutical field. | 2010-12-09 |
| 20100311771 | METHOD OF TREATING MOVEMENT DISORDERS USING BARBITURIC ACID DERIVATIVES - A method of treating movement disorders comprises administering to a human or animal subject in need of treatment a therapeutically effective amount of at least one compound according to the following formula: | 2010-12-09 |
| 20100311772 | METHOD AND COMPOUNDS FOR INHIBITION OF CELL DEATH - The invention is directed to methods and compositions for inhibiting caspase-independent apoptosis. In particular, methods and compositions for inhibiting Omi/HtrA2 activity, as well as method for identifying other inhibitors of Omi/HtrA2. Also disclosed are Omi/HtrA2 specific substrates and methods for identifying other substrates of Omi/HtrA2. | 2010-12-09 |
| 20100311773 | NOVEL ANABASEINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF - Disclosed are novel anabaseine derivatives that act as agonists of the α7 nAChR. Also disclosed are pharmaceutical compositions, methods of treating inflammatory conditions, methods of treating CNS disorders, methods for inhibiting cytokine release from mammalian cells and methods for the preparation of the novel compounds. | 2010-12-09 |
| 20100311774 | Combination Comprising Paclitaxel for Treating Ovarian Cancer - The invention relates to the combination of an endothelin receptor antagonist of formula (I) with paclitaxel, and in particular to this combination for therapeutic use, simultaneously, separately or over a period of time, in the treatment of ovarian cancer. | 2010-12-09 |
